Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catheter Precision (VTAK) Research & Development (2017 - 2025)

Catheter Precision (VTAK) has disclosed Research & Development for 8 consecutive years, with $276000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 338.1% to $276000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $625000.0, a 267.65% increase, with the full-year FY2024 number at $272000.0, down 42.74% from a year prior.
  • Research & Development was $276000.0 for Q3 2025 at Catheter Precision, up from $155000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.7 million in Q4 2021 to a low of -$11000.0 in Q4 2023.
  • A 5-year average of $1.0 million and a median of $155000.0 in 2025 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: tumbled 107.14% in 2023, then surged 927.27% in 2024.
  • Catheter Precision's Research & Development stood at $3.7 million in 2021, then crashed by 95.87% to $154000.0 in 2022, then crashed by 107.14% to -$11000.0 in 2023, then soared by 927.27% to $91000.0 in 2024, then skyrocketed by 203.3% to $276000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Research & Development are $276000.0 (Q3 2025), $155000.0 (Q2 2025), and $103000.0 (Q1 2025).